~$220M Annual run-rate cost reduction

ir_statement / Sep 14, 2026 / receipt

Children treated increased > 20% Y/Y globally

ir_statement / Sep 14, 2026 / receipt

Double-digit U.S. and OUS revenue growth and strong 2H outlook led to increased FY’26 VOXZOGO guidance

ir_statement / Sep 14, 2026 / receipt

Based on current rates, interest expense associated with Amicus financing is estimated at approximately $200 million on an annualized basis

ir_statement / Sep 14, 2026 / receipt

Due to cash and investments used to fund the acquisition, interest income expected to decrease year-over-year, in near-term

ir_statement / Sep 14, 2026 / receipt

GAAP SG&A includes ~$84M of transaction- and integration-related charges associated with the Amicus acquisition, which are excluded from Non-GAAP results

ir_statement / Sep 14, 2026 / receipt

FY’26 Non-GAAP Diluted EPS guidance increased; Total Revenues midpoint raised

ir_statement / Sep 14, 2026 / receipt

Represents approximately $280 million of cost reductions on a GAAP basis, and approximately $220 million of cost reductions on a Non-GAAP basis, expected to be fully realized in 2028, representing an

ir_statement / Sep 14, 2026 / receipt

Significant cost synergies1,2 expected to be fully realized in 2028

ir_statement / Sep 14, 2026 / receipt

strong U.S. and global demand led to increased full-year guidance of at least $1 billion

ir_statement / Sep 14, 2026 / receipt

Significant Cost Synergies Expected to be Fully Realized in 2028

ir_statement / Sep 14, 2026 / receipt

Goal to establish more than 20 new markets over time

ir_statement / Sep 14, 2026 / receipt